Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Medtronic
Chinese Patent Office
Deloitte
US Department of Justice
Moodys
Julphar
Johnson and Johnson
Boehringer Ingelheim

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,889,191

« Back to Dashboard

Which drugs does patent 8,889,191 protect, and when does it expire?

Patent 8,889,191 protects TROKENDI XR and is included in one NDA.

This patent has eleven patent family members in eight countries.
Summary for Patent: 8,889,191
Title:Sustained-release formulations of topiramate
Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
Inventor(s): Liang; Likan (Boyds, MD), Wang; Hua (Clarksville, MD), Bhatt; Padmanabh P. (Rockville, MD), Vieira; Michael L. (Gaithersburg, MD)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:12/926,936
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,889,191
Patent Claim Types:
see list of patent claims
Use; Formulation; Composition; Delivery; Dosage form;

Drugs Protected by US Patent 8,889,191

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-001 Aug 16, 2013 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF EPILEPSY ➤ Sign Up
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-001 Aug 16, 2013 AB RX Yes No ➤ Sign Up ➤ Sign Up USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE ➤ Sign Up
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF EPILEPSY ➤ Sign Up
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 AB RX Yes No ➤ Sign Up ➤ Sign Up USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,889,191

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,877,248 Sustained-release formulations of topiramate ➤ Sign Up
9,549,940 Sustained-release formulations of topiramate ➤ Sign Up
9,555,004 Sustained-release formulations of topiramate ➤ Sign Up
8,298,576 Sustained-release formulations of topiramate ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Cerilliant
Farmers Insurance
Medtronic
Chinese Patent Office
UBS
Express Scripts
Fish and Richardson
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.